ReviewYonsei medical journal2011
Multidrug-resistant Acinetobacter spp.: increasingly problematic nosocomial pathogens.
Review in Yonsei medical journal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 1 synthesis or guideline pooled it, 137 citations in OpenAlex.
- Restoring nature with microbes: bioremediation in the world's biodiversity hotspots.Applied and environmental microbiology · 2025Pooled it
- Microbiome analysis reveals the potential mechanism of herbal sitz bath complementary therapy in accelerating postoperative recovery from perianal abscesses.IET systems biologyTrial
- Physicians' understanding of antibiotic prescribing in Korean long-term care hospitals: a multicenter cross-sectional study.Journal of health, population, and nutrition · 2026Article
- Clinical Implications of Bacteremia Caused by Non-Biomedicines · 2025Article
- Clinical Case-control Study of Postoperative Ocular Microbiota Colonization Using Microbial Analysis in Patients Undergoing Blepharoplasty.Plastic and reconstructive surgery. Global open · 2025Article
- Molecular Mechanisms of Bacterial Resistance to Antimicrobial Peptides in the Modern Era: An Updated Review.Microorganisms · 2024Review
- Carbapenem-resistantInfection & chemotherapy · 2024Article
- Treatment Strategies of Colistin ResistanceAntibiotics (Basel, Switzerland) · 2024Review
- Characterization of aFrontiers in cellular and infection microbiology · 2024Article
- A Review of Resistance to Polymyxins and Evolving Mobile Colistin Resistance Gene (Antibiotics (Basel, Switzerland) · 2023Review
- Ecology and resistance to UV light and antibiotics of microbial communities on UV cabins in the dermatology service of a Spanish hospital.Scientific reports · 2023Article
- Mobile genetic elements carrying aminoglycoside resistance genes inFrontiers in microbiology · 2023Article
- Characterization ofBiology · 2022Article
- Rapid identification of carbapenemases by CarbAcineto NP test and the rate of beta-lactamases amongIranian journal of microbiology · 2022Article
- A subtractive proteomics approach for the identification of immunodominantFrontiers in immunology · 2022Article
- Prevalence of Aminoglycoside Resistance and Aminoglycoside Modifying Enzymes inInfection and drug resistance · 2021Article
- Evaluation of a Rapid and Simplified Protocol for Direct Identification of Microorganisms From Positive Blood Cultures by Using Matrix Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS).Frontiers in cellular and infection microbiology · 2021Article
- Sequential Hypertonic-Hypotonic Treatment Enhances Efficacy of Antibiotic againstAntibiotics (Basel, Switzerland) · 2020Article
- Role of plasmid carrying3 Biotech · 2020Article
- Emergent Polymyxin Resistance: End of an Era?Open forum infectious diseases · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pathogenic bacteria have increasingly been resisting to antimicrobial therapy. Recently, resistance problem has been relatively much worsened in Gram-negative bacilli. Acinetobacter spp. are typical nosocomial pathogens causing infections and high mortality, almost exclusively in compromised hospital patients. Acinetobacter spp. are intrinsically less susceptible to antibiotics than Enterobacteriaceae, and have propensity to acquire resistance. A surveillance study in Korea in 2009 showed that resistance rates of Acinetobacter spp. were very high: to fluoroquinolone 67%, to amikacin 48%, to ceftazidime 66% and to imipenem 51%. Carbapenem resistance was mostly due to OXA type carbapenemase production in A. baumannii isolates, whereas it was due to metallo-β-lactamase production in non-baumannii Acinetobacter isolates. Colistin-resistant isolates were rare but started to be isolated in Korea. Currently, the infection caused by multidrug-resistant A. baumannii is among the most difficult ones to treat. Analysis at tertiary care hospital in 2010 showed that among the 1,085 isolates of Acinetobacter spp., 14.9% and 41.8% were resistant to seven, and to all eight antimicrobial agents tested, respectively. It is known to be difficult to prevent Acinetobacter spp. infection in hospitalized patients, because the organisms are ubiquitous in hospital environment. Efforts to control resistant bacteria in Korea by hospitals, relevant scientific societies and government agencies have only partially been successful. We need concerted multidisciplinary efforts to preserve the efficacy of currently available antimicrobial agents, by following the principles of antimicrobial stewardship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.